Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $23.30

Rapport Therapeutics (NASDAQ:RAPP) shares gapped up prior to trading on Friday . The stock had previously closed at $23.30, but opened at $24.14. Rapport Therapeutics shares last traded at $23.82, with a volume of 22,449 shares.

Analyst Ratings Changes

A number of brokerages have commented on RAPP. Stifel Nicolaus initiated coverage on Rapport Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $35.00 price target on the stock. Jefferies Financial Group started coverage on Rapport Therapeutics in a report on Tuesday. They set a “buy” rating and a $35.00 target price on the stock. Finally, TD Cowen assumed coverage on shares of Rapport Therapeutics in a research note on Tuesday. They issued a “buy” rating for the company.

Rapport Therapeutics Trading Up 3.9 %

Insider Activity

In other Rapport Therapeutics news, Director James Healy acquired 44,032 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were bought at an average price of $24.52 per share, with a total value of $1,079,664.64. Following the completion of the acquisition, the director now owns 40,851 shares in the company, valued at approximately $1,001,666.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.